Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10566 in High-risk Non-muscle-invasive Bladder Cancer
NCT07468851Phase 2Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10566 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Hansoh Pharmaceutical Group. Started Aug 2026; status: recruiting.
02
Drugs
HS-10566
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07468851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07468851.